VWF and acquired thrombotic thrombocytopenic purpura: Interestingly, in August 2018, Caplacizumab, a Nb directed against von Willebrand Factor (vWF), was EMA-approved for acquired thrombotic thrombocytopenic purpura (aTTP) [48,88].